MSMichael L. Shuler

Michael L. Shuler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Recognitions

Top Cited Scholar (2025)

Michael L. Shuler has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development of a Microphysiological System to Model Human Cancer Metastasis From the Colon to the Liver

    by Paula G. Miller, Emina Huang, Robert Fisher, Michael L. Shuler

    We describe a novel device to mimic the metastasis of cancer cells from the colon into the liver in a human model. The colon mimic is connected to the liver model by a gravity‐driven recirculating unidirectional flow of a blood surrogate and can mimic the five steps of the metastatic cascade: invasion in the colon, intravasation into the bloodstream, systemic transportation, extravasation into the liver, and colonization in the liver. The colon mimic uses established normal colon epithelial organoid cells (NL) and human umbilical vein endothelial cells (HUVEC) plated on opposite sides of a membrane. To better mimic the colon structure the NL side of the membrane is exposed to air to establish an air‐liquid interface. The liver mimic consists of human liver sinusoidal endothelial cells (HHSEC) and epithelial hepatic cells (HepG2 C3A) plated in Matrigel on opposite sides of a membrane. Labeled colorectal cancer cells/clusters (CA) from organoids are introduced into an established normal colon epithelial cell (NL) layer from the same patient before assembly of the system or alternatively NL organoids and fluorescently labeled CA organoids from the same patient were prepared as a ratio of 10:1 NL:CA and established together before assembly of the system. Cell viability is greater than 85% in this system. We demonstrate that over 5 days of operation that the five steps of the metastatic cascade are replicated. This novel device allows an in vitro estimate of metastatic capability (as measured by using percentages of the labeled areas per device through ImageJ) in response to selected variables. In this study, the metastatic capability depends on the source of cancer cells (e.g., the patient), the clumping of cancer cells, glucose concentration, and oxygen levels (hypoxia). For the first time, this new in vitro system mimics all five steps of the metastatic cascade in a single device and provides a new device to probe and observe the process of metastasis in a human‐based model in only 5 days. The rapid observation is due to the use of a high concentration of cancer cells in the colon (e.g. 10%) and the absence of the immune system. Our device makes it possible to probe aspects of each step of metastasis and interactions between steps.


  • Top Cited Papers
    Open Access

    A guide to the organ-on-a-chip

    by Chak Ming Leung, Pim de Haan, Kacey Ronaldson-Bouchard, Ge-Ah Kim, Jihoon Ko, Hoon Suk Rho, Zhu Chen, Pamela Habibovic, Noo Li Jeon, Shuichi Takayama, et al.


  • Potential of Plant Cell Culture for Taxane Production*

    by Donna M. Gibson, Raymond E. B. Ketchum, Thomas J. Hirasuna, Michael L. Shuler

    The bark of Taxus brevifolia (Pacific yew) is the current source for the novel chemotherapeutic drug Taxol. Taxol, a complex diteipenoid, has been called by the NCI “the best anti-cancer agent” developed in the last 15 years. The primary impediment to the development and utilization of Taxol as a chemotherapeutic, however, has been its supply.1 Supplies of the drug are limited in part because of the restrictions on the amount of material available for harvesting.2 Additionally, the complex structure of Taxol has eluded complete chemical synthesis, although significant progress has been made as seen in Chapter 6.3 Although semisynthetic production of Taxol appears promising, this method is still dependent on a natural source for the taxane ring precursor.4,5

  • Pumpless, unidirectional microphysiological system for testing metabolism‐dependent chemotherapeutic toxicity

    by Danielle J. LaValley, Paula G. Miller, Michael L. Shuler

    Drug development is often hindered by the failure of preclinical models to accurately assess and predict the efficacy and safety of drug candidates. Body‐on‐a‐chip (BOC) microfluidic devices, a subset of microphysiological systems (MPS), are being created to better predict human responses to drugs. Each BOC is designed with separate organ chambers interconnected with microfluidic channels mimicking blood recirculation. Here, we describe the design of the first pumpless, unidirectional, multiorgan system and apply this design concept for testing anticancer drug treatments. HCT‐116 colon cancer spheroids, HepG2/C3A hepatocytes, and HL‐60 promyeloblasts were embedded in collagen hydrogels and cultured within compartments representing “colon tumor”, “liver,” and “bone marrow” tissue, respectively. Operating on a pumpless platform, the microfluidic channel design provides unidirectional perfusion at physiologically realistic ratios to multiple channels simultaneously. The metabolism‐dependent toxic effect of Tegafur, an oral prodrug of 5‐fluorouracil, combined with uracil was examined in each cell type. Tegafur‐uracil treatment induced substantial cell death in HCT‐116 cells and this cytotoxic response was reduced for multicellular spheroids compared to single cells, likely due to diffusion‐limited drug penetration. Additionally, off‐target toxicity was detected by HL‐60 cells, which demonstrate that such systems can provide useful information on dose‐limiting side effects. Collectively, this microscale cell culture analog is a valuable physiologically‐based pharmacokinetic drug screening platform that may be used to support cancer drug development.


  • Open Access

    A Tissue Engineering Approach to Metastatic Colon Cancer

    by Samaneh Kamali Sarvestani, Reece K. DeHaan, Paula G. Miller, Shree Bose, Xiling Shen, Michael L. Shuler, Emina H. Huang


  • Organ-on-a-chip systems: translating concept into practice

    by Michael L. Shuler

    Thought leader Michael Shuler provides an update on the Lab on a Chip thematic collection organ-on-a-chip systems: translating concept into practice.


  • Multiorgan microfluidic platform with breathable lung chamber for inhalation or intravenous drug screening and development

    by Paula G. Miller, Chen‐Yu Chen, Ying I. Wang, Emily Gao, Michael L. Shuler

    Efficient and economical delivery of pharmaceuticals to patients is critical for effective therapy. Here we describe a multiorgan (lung, liver, and breast cancer) microphysiological system (“Body‐on‐a‐Chip”) designed to mimic both inhalation therapy and/or intravenous therapy using curcumin as a model drug. This system is “pumpless” and self‐contained using a rocker platform for fluid (blood surrogate) bidirectional recirculation. Our lung chamber is constructed to maintain an air‐liquid interface and contained a “breathable” component that was designed to mimic breathing by simulating gas exchange, contraction and expansion of the “lung” using a reciprocating pump. Three cell lines were used: A549 for the lung, HepG2 C3A for the liver, and MDA MB231 for breast cancer. All cell lines were maintained with high viability (>85%) in the device for at least 48 hr. Curcumin is used to treat breast cancer and this allowed us to compare inhalation delivery versus intravenous delivery of the drug in terms of effectiveness and potentially toxicity. Inhalation therapy could be potentially applied at home by the patient while intravenous therapy would need to be applied in a clinical setting. Inhalation therapy would be more economical and allow more frequent dosing with a potentially lower level of drug. For 24 hr exposure to 2.5 and 25 µM curcumin in the flow device the effect on lung and liver viability was small to insignificant, while there was a significant decrease in viability of the breast cancer (to 69% at 2.5 µM and 51% at 25 µM). Intravenous delivery also selectively decreased breast cancer viability (to 88% at 2.5 µM and 79% at 25 µM) but was less effective than inhalation therapy. The response in the static device controls was significantly reduced from that with recirculation demonstrating the effect of flow. These results demonstrate for the first time the feasibility of constructing a multiorgan microphysiological system with recirculating flow that incorporates a “breathable” lung module that maintains an air‐liquid interface.


  • Open Access

    Correction: UniChip enables long-term recirculating unidirectional perfusion with gravity-driven flow for microphysiological systems

    by Ying I. Wang, Michael L. Shuler

    Correction for ‘UniChip enables long-term recirculating unidirectional perfusion with gravity-driven flow for microphysiological systems’ by Ying I. Wang and Michael L. Shuler, Lab Chip, 2018, 18, 2563–2574.


  • Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics

    by Christopher W. McAleer, Christopher J. Long, Daniel Elbrecht, Trevor Sasserath, L. Richard Bridges, John W. Rumsey, Candace Martin, Mark Schnepper, Ying Wang, Franz Schuler, et al.

    An in vitro multi-organ system evaluates the efficacy and potential off-target toxicities of anticancer parent drugs and metabolites.


  • Mimicking the Human Physiology with Microphysiological Systems (MPS)

    by Jong Hwan Sung, Jamin Koo, Michael L. Shuler